SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ — Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the late-breaking abstract on the AND017 Phase 2 clinical trial for treatment of anemia in dialysis-dependent chronic kidney disease (DD-CKD) was accepted to present at the annual meeting of American Society of Nephrology (ASN) Kidney Week in San Diego on October 24-27, 2024. Three other posters about the results of AND017 Phase 1 in healthy volunteers and Phase 2 for treatment of anemia in non-dialysis dependent chronic kidney disease (NDD-CKD) were also accepted to present previously.
Details of the presentations are listed below:
KIND presentations at ASN in San Diego (Kidney Week 2024):
Abstract title
Abstract #
Poster board #
Presenting/lead author
Presentation date andtime
Session Title
Efficacy and Safety of AND017 for Treatment of Anemia in Dialysis-Dependent CKD
4176548
TH-PO1181
Yusha Zhu
Thursday, Oct 24, 10:00am-12:00pm PDT
Late-Breaking Science Posters [LB-PO]
First-in-Human Study of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) AND017 in Healthy Participants
4122116
TH-PO896
Yusha Zhu
Thursday, Oct 24, 10:00am-12:00pm PDT
Anemia and Iron Metabolism [PO0200]
Effect of Food on the Pharmacokinetics of AND017 in a Phase I Study
4122852
TH-PO897
Yusha Zhu
Thursday, Oct 24, 10:00am-12:00pm PDT
Anemia and Iron Metabolism [PO0200]
Safety and Efficacy of AND017, a Hypoxia Inducible Factor-Prolyl-Hydroxylase Inhibitor (HIF-PHI), in patients with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
4124344
TH-PO898
Yusha Zhu
Thursday, Oct 24, 10:00am-12:00pm PDT
Anemia and Iron Metabolism [PO0200]
About AND017
AND017 is a first-in-class hemoglobin elevating agent (HbEA) that targets multiple stages of the red blood cell (RBC) life cycle and is being developed to treat anemia associated with dialysis-dependent chronic kidney disease (DD-CKD), non-dialysis dependent chronic kidney disease (NDD-CKD), cancer-related anemia (CRA), myelodysplastic syndromes (MDS) anemia, sickle cell disease (SCD), and β-thalassemia.
About Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC")
KIND is a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers. The company’s mission, "kind to human, humble to science, good to patients", drives its commitment to advancing current science to meet unmet medical need. KIND’s lead clinical candidate, AND017, first-in-class hemoglobin elevating agent (HbEA), is being developed for treating anemia of various disorders, including dialysis dependent chronic kidney disease (DD-CKD) associated anemia, non-dialysis dependent (NDD) CKD associated anemia, cancer related anemia (CRA), myelodysplastic syndromes (MDS) anemia, sickle cell disease (SCD), and β-thalassemia. KIND’s second clinical candidate, AND019, an orally available brain penetrant selective estrogen receptor degrader (SERD), is being developed to treat ER+/Her2- breast cancer. KIND is also developing promising disruptive next generation ADC technologies. For details, please visit http://en.kindpharmaceutical.com.
Contact:Dong Liu, PhD, Chairman and CEO of Kind PharmaceuticalEmail: liudong@kindpharmaceutical.comTel: 650-315 6151
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network